search
Liquidia
Trends
- 1Liquidia shares slump after US court ruling for United Therapeutics▼Liquidia slumps after US court rules for United Therapeutics in patent fight
Liquidia shares fell after a US court ruled in favour of United Therapeutics in a long-running patent dispute between the two pharmaceutical companies. The ruling is a blow to Liquidia and could affect its ability to compete in the US market. Investors reacted quickly, sending the stock down sharply on the news.
- 2Liquidia Shares Plunge 57% After Delaware Court Ruling▼Liquidia Stock Crashed 57% in a Day After a Delaware Court Ruling. An Appeal Could Decide Whether Shares Rebound.
Liquidia shares collapsed 57% in a single trading day following a ruling by a Delaware court, wiping out a large portion of the biotech's market value. Investors are now watching whether an appeal could reverse the decision and allow the stock to recover. The case centers on a legal dispute with implications for the company's key product.
- 3Liquidia Shares Fall Again After US Patent Court Ruling●Liquidia Stock Extends Slide Following US Court Ruling in Patent Dispute
Liquidia shares extended their decline after a US court ruling in an ongoing patent dispute. The decision adds to pressure on the pharmaceutical company, whose lead product has faced legal challenges from a larger competitor. Investors continued selling the stock as the court's outcome raised fresh uncertainty over the company's commercial prospects and patent protections.
- 4Court ruling favours United Therapeutics over Liquidia in patent fight●Court ruling boosts United Therapeutics, slams Liquidia over pulmonary hypertension drug patent.
A court has ruled in favour of United Therapeutics in its patent dispute with Liquidia over a drug for pulmonary hypertension. The decision blocks Liquidia's competing treatment and strengthens United Therapeutics' position in the market. Investors reacted quickly, with United Therapeutics shares rising while Liquidia faced losses, and analysts are weighing the implications for future generic competition.
- 5Liquidia shares plunge after court ruling in United Therapeutics patent fight●Liquidia plunges amid court ruling in United Therapeutics patent fight
Liquidia's stock fell sharply following a court ruling in its long-running patent dispute with United Therapeutics over its lead pulmonary hypertension drug. The litigation, centered on United Therapeutics' claims that Liquidia infringed patents tied to treprostinil therapies, has weighed on the company for years, and investors reacted quickly to the latest adverse development in court.